Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

2,425

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

November 23, 2023

Study Completion Date

November 30, 2023

Conditions
Stroke, AcuteCerebrovascular Disorders
Interventions
DRUG

urapidil

A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.

Trial Locations (4)

100088

The George Institute for Global Health, Beijing

200123

Shanghai East Hospital, Shanghai

610000

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China, Chengdu

610500

The First Affliated Hospital of Chengdu Medical College, Chengdu

All Listed Sponsors
collaborator

Shanghai East Hospital, China

UNKNOWN

collaborator

First Affiliated Hospital of Chengdu Medical College, China

UNKNOWN

collaborator

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China

UNKNOWN

lead

The George Institute for Global Health, China

OTHER

NCT03790800 - Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial | Biotech Hunter | Biotech Hunter